Followers | 1321 |
Posts | 26906 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Thursday, April 18, 2019 9:34:24 AM
CBD Life Sciences Subsidiary Enters Into Negotiations to Enter Japanese Market
8:00 AM ET 4/18/19 | GlobeNewswire
Related Quotes
9:33 AM ET 4/18/19
Symbol Last % Chg
CBDL
0.02 125.61%
Real time quote.
CBD Life Sciences Subsidiary Enters Into Negotiations to Enter Japanese Market
SCOTTSDALE, ARIZONA, April 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CBD Life Sciences Inc. (OTC:CBDL) is pleased to announce that its wholly owned subsidiary, LBC Bioscience has entered into negotiations to distribute its line of products in Japan. The negotiations are anticipated to close within the next two weeks with an initial order of $250,000.
Japan's market for CBD products is growing at almost 100% year-over-year with annual supplement sales valued at over $10 billion. Japan's consumer economy is very health conscious, sophisticated, comprised of an aging population with an early adoption of CBD nutraceuticals.
"We are very excited about this opportunity to enter the Japanese market, " commented Lisa Nelson, President & CEO of CBD Life Science. "The Japanese have embraced the benefits of CBD and we want to be on the forefront providing quality products to this aggressive expanding market, " continued Ms. Nelson.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol 'CBDL'. The Company's main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.
About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions, supplements, edibles, and a full line of pet products. In addition, LBC is in the process of developing an anti-aging skin product line. LBC's products can be viewed and purchased on the company's website at www.lbcbioscienceinc.com.
Contact Information
Investor Relations
Ten Associates LLC
11529 N. 120th St.
Scottsdale, Arizona
85259 USA
Telephone: 480-326-8577
Contact: Thomas E. Nelson
Email: tenassociates33@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
> Dow Jones Newswires
April 18, 2019 08:00 ET (12:00 GMT)
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM